[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
2. Krishnamurthy S, Sneige N, Thompson PA, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM: Nipple aspirate fluid cytology in breast carcinoma. Cancer; 2003 Apr 25;99(2):97-104
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate fluid cytology in breast carcinoma.
  • BACKGROUND: Nipple aspirate fluid (NAF) cytology is a simple noninvasive method to study cells exfoliated into the ductal system of the breast.
  • In the current study, the significance of cytologic findings in NAF was determined by correlating them with histopathologic findings from corresponding breast tissue.
  • METHODS: Nipple aspirate fluid was collected by breast massaging and by using a breast aspiration device from 74 women with biopsy confirmed intraductal or invasive carcinoma with or without a history of preoperative neoadjuvant chemotherapy.
  • Cytologic findings were categorized as insufficient for diagnosis (less than 10 epithelial cells), benign, mild atypia, marked atypia or suspicious, and malignant.
  • Finally, they were correlated with tissue findings.
  • RESULTS: Nipple aspirate fluid was obtained from 74 women, including 24 who had received preoperative neoadjuvant chemotherapy.
  • Patients treated with chemotherapy had fewer epithelial cells in their NAF compared with patients who were not treated with chemotherapy.
  • Thirty specimens (41%) were inadequate for diagnosis, 34 were (46%) benign, 5 (7%) were mildly atypical, 1 (1%) was markedly atypical, and 4 (5%) were malignant.
  • Of the five cases with mildly atypical cytology, three were intraductal papilloma, one was low-grade papillary intraductal carcinoma, and one was low-grade intracystic papillary carcinoma with invasion in the corresponding tissue specimen.
  • The single case with markedly atypical NAF cytology had extensive ductal carcinoma in situ (DCIS).
  • Of the four cases with malignant NAF cytology, two were extensive DCIS and two had invasive carcinoma with extensive DCIS in the breast specimen.
  • Nipple aspirate fluid is not a sensitive test for detecting invasive carcinoma of the breast.
  • Atypical cytology in NAF is associated with papillary lesions in the underlying breast.
  • [MeSH-major] Breast / cytology. Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Nipples

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12704689.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Yen TW, Hunt KK, Mirza NQ, Thomas ES, Singletary SE, Babiera GV, Meric-Bernstam F, Buchholz TA, Feig BW, Ross MI, Ames FC, Theriault RL, Kuerer HM: Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer; 2004 Mar 1;100(5):942-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
  • BACKGROUND: To date, the impact of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 trial reported in 1999 on the use of tamoxifen after surgery for ductal carcinoma in situ (DCIS) is unknown.
  • Whether patients were offered tamoxifen, whether patients accepted tamoxifen, and the associated reasons were recorded along with tamoxifen-related side effects and patient compliance with therapy.
  • RESULTS: Of the 350 patients, 73 were excluded because of evidence of invasive carcinoma on final pathology review.
  • Of 111 patients who were not offered tamoxifen, 39 patients (35%) had documented explanations, which included bilateral mastectomy (n = 25 patients), medical reasons (n = 10 patients), and already received tamoxifen for other reasons at the time of diagnosis (n = 4 patients).
  • CONCLUSIONS: Physicians and patients remain cautious regarding the use of tamoxifen after local treatment for DCIS.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Tamoxifen / administration & dosage
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Female. Health Planning Guidelines. Humans. Immunohistochemistry. Mastectomy, Segmental / methods. Middle Aged. Neoplasm Staging. Patient Participation. Patient Selection. Physician-Patient Relations. Probability. Prognosis. Prospective Studies. Registries. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 14983489.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


Advertisement
4. Tozaki M, Uno S, Kobayashi T, Aiba K, Yoshida K, Takeyama H, Shioya H, Tabei I, Toriumi Y, Suzuki M, Kawakami M, Fukuda K: Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI. Radiat Med; 2004 Jul-Aug;22(4):246-53
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI.
  • PURPOSE: To evaluate the efficacy of dynamic multidetector-row CT (MDCT) in assessing residual cancer extent after neoadjuvant chemotherapy (NAC), and to compare MDCT results with those derived from dynamic three-dimensional MRI using the volumetric interpolated breath-hold examination (VIBE) sequence.
  • MATERIALS AND METHODS: MDCT before and after NAC was performed in 19 consecutive patients with breast cancer.
  • In replaced lesions, accuracy for the detection of tumor extent with a deviation of less than 2 cm in length was 0% (0/7) with early-phase CT/MRI and 100% (7/7) with late-phase CT/MRI.
  • One case of ductal carcinoma in situ (DCIS) could be detected only with late phase MRI.
  • CONCLUSION: Late-phase images obtained by MDCT and MRI may be accurate in the diagnosis of residual cancer extent after NAC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods. Neoadjuvant Therapy. Tomography, Spiral Computed
  • [MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Bridged Compounds / administration & dosage. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Contrast Media. Female. Humans. Image Enhancement / methods. Imaging, Three-Dimensional. Middle Aged. Neoplasm, Residual. Radiographic Image Enhancement / methods. Remission Induction. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15468945.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Bridged Compounds; 0 / Contrast Media; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


5. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ: Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat; 2010 Jan;119(1):137-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
  • The purpose of this study is to determine the biologic impact of short-term lipophilic statin exposure on in situ and invasive breast cancer through paired tissue, blood and imaging-based biomarkers.
  • A perioperative window trial of fluvastatin was conducted in women with a diagnosis of DCIS or stage 1 breast cancer.
  • Tissue (diagnostic core biopsy/final surgical specimen), blood, and magnetic resonance images were obtained before/after treatment.
  • Fluvastatin showed measurable biologic changes by reducing tumor proliferation and increasing apoptotic activity in high-grade, stage 0/1 breast cancer.
  • These results support further evaluation of statins as chemoprevention for ER-negative high grade breast cancers.
  • [MeSH-major] Apoptosis. Breast Neoplasms / drug therapy. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Fatty Acids, Monounsaturated / therapeutic use. Gene Expression Regulation, Neoplastic. Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use. Indoles / therapeutic use
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / biosynthesis. Caspase 3 / biosynthesis. Cell Proliferation / drug effects. Female. Humans. Ki-67 Antigen / biosynthesis. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1504 [12359860.001]
  • [Cites] J Clin Epidemiol. 2003 Mar;56(3):280-5 [12725884.001]
  • [Cites] Lancet. 2003 Jun 14;361(9374):2005-16 [12814710.001]
  • [Cites] Lancet. 2004 Mar 6;363(9411):757-67 [15016485.001]
  • [Cites] Circ Res. 1991 Apr;68(4):1027-34 [2009605.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] JAMA. 1997 Jul 23-30;278(4):313-21 [9228438.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8880-5 [9671773.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Magn Reson Imaging Clin N Am. 1999 May;7(2):411-20, x [10382170.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21926-31 [10419514.001]
  • [Cites] JAMA. 1999 Dec 22-29;282(24):2340-6 [10612322.001]
  • [Cites] J Investig Med. 2004 May;52(4):248-53 [15521546.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:89-118 [15822172.001]
  • [Cites] Am J Cardiol. 2005 Sep 5;96(5A):24F-33F [16126020.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1267-78 [16214597.001]
  • [Cites] Arch Intern Med. 2005 Oct 24;165(19):2264-71 [16246993.001]
  • [Cites] Circ Res. 2000 Sep 29;87(7):526-8 [11009552.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Am J Med. 2006 Apr;119(4 Suppl 1):S3-S11 [16563939.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):700-7 [16705124.001]
  • [Cites] JAMA. 2006 Jun 21;295(23):2727-41 [16754727.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8707-14 [16951186.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):833-43 [17131313.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):213-9 [17235211.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):416-21 [17372235.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):220-8 [17125918.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7386-94 [17671209.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):27-33 [18008366.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):134-9 [18182618.001]
  • [Cites] Trends Mol Med. 2008 Jan;14(1):37-44 [18068482.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Eur J Cancer Prev. 2008 Jun;17(3):259-68 [18414198.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jun;109(3):573-9 [17674197.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33 [18463402.001]
  • [Cites] Ann Surg Oncol. 2001 Aug;8(7):580-5 [11508619.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1357-66 [18765432.001]
  • [Cites] Int J Cardiol. 2002 Nov;86(1):5-18 [12243846.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):285-8 [12163444.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8606-12 [16260694.001]
  • (PMID = 19728082.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA125183; United States / NCI NIH HHS / CA / P50 CA125183-01; United States / NCI NIH HHS / CA / R01 CA116182
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Fatty Acids, Monounsaturated; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Indoles; 0 / Ki-67 Antigen; 4L066368AS / fluvastatin; 9007-41-4 / C-Reactive Protein; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS594101; NLM/ PMC4087110
  •  go-up   go-down


6. Stearns V, Coop A, Singh B, Gallagher A, Yamauchi H, Lieberman R, Pennanen M, Trock B, Hayes DF, Ellis MJ: A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia. Clin Cancer Res; 2004 Nov 15;10(22):7583-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia.
  • PURPOSE: Efficient strategies to screen promising agents in early phase development are essential for rapid progress in breast cancer chemoprevention.
  • We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol, using the "window" between diagnostic and definitive surgery.
  • EXPERIMENTAL DESIGN: Eligible patients included those with a diagnosis of atypical ductal hyperplasia, ductal carcinoma in situ, lobular carcinoma in situ, or invasive carcinoma (<3 cm in size) that required further surgery.
  • The power to observe changes in candidate SEB was diminished by a 44% incidence of cases in which the index lesion was not present in the definitive surgical specimen.
  • CONCLUSIONS: Preoperative POH exposure was safe and suitable for a more definitive phase II SEB study.
  • Further investigations must overcome logistical obstacles to accrual, and they must focus on approaches to maximize tissue collection and to incorporate genomic analysis of target lesions.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Breast Neoplasms / drug therapy. Monoterpenes / therapeutic use
  • [MeSH-minor] Aged. Apoptosis. Biomarkers. Biopsy. Carcinoma in Situ. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Cell Proliferation. Cohort Studies. Female. Humans. Immunohistochemistry. Middle Aged. Pilot Projects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15569989.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-65003
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Monoterpenes; 319R5C7293 / perilla alcohol
  •  go-up   go-down


7. Sauter ER, Ehya H, Mammen A, Klein G: Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy. Br J Cancer; 2001 Dec 14;85(12):1952-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy.
  • We previously demonstrated that abnormal nipple aspirate fluid (NAF) cytology predicted residual breast cancer (RC) and tumour size after excisional biopsy (EB), although normal NAF cytology did not exclude RC.
  • LN metastases provide prognostic information allowing medical and radiation oncologists to determine the need for adjuvant therapy.
  • NAF cytology and pathologic parameters: tumour distance from biopsy margins, multifocal and multicentric disease, sub-type of ductal carcinoma in situ (DCIS) or invasive cancer (IC), grade of DCIS or IC, tumour and specimen size, tumour and biopsy cavity location, presence or absence of extensive DCIS, and biopsy scar distance from the nipple were evaluated bivariately and then by logistic regression (LR) for their association with RC and involved LN (> or = 1 (+) LN, useful to determine chemotherapy need, and > or = 4 (+) LN, useful to determine radiation need to the chest and axilla).
  • We propose an algorithm which, if confirmed in a larger study, may allow clinicians to be more selective in their recommendations of re-excision breast biopsy or mastectomy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(7):1222-7 [10584885.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):829-34 [1168727.001]
  • [Cites] Am J Clin Pathol. 1975 Dec;64(6):728-38 [1202937.001]
  • [Cites] J Natl Cancer Inst. 1983 Dec;71(6):1115-21 [6581355.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] Semin Surg Oncol. 1992 May-Jun;8(3):122-8 [1496221.001]
  • [Cites] Arch Surg. 1993 Sep;128(9):1014-8; discussion 1018-20 [8396387.001]
  • [Cites] Ann Surg. 1993 Dec;218(6):729-34 [8257222.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):130-41 [1536131.001]
  • (PMID = 11747339.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 87391
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2364009
  •  go-up   go-down


8. Wasserberg N, Morgenstern S, Schachter J, Fenig E, Lelcuk S, Gutman H: Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component. Arch Surg; 2002 Nov;137(11):1249-52
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for lymph node metastases in breast ductal carcinoma in situ with minimal invasive component.
  • HYPOTHESIS: Clinical and pathological variables may be predictors of axillary dissemination in T1mic and T1a breast carcinoma.
  • PATIENTS: All patients diagnosed as having ductal carcinoma in situ (DCIS) with microinvasion between January 1, 1988, and December 30, 1998.
  • Modified radical mastectomy was performed in 29 patients (18 with T1mic and 11 with T1a) and breast-preserving surgery in 28 (19 with T1mic and 9 with T1a).
  • Forty-seven patients received adjuvant therapy (radiotherapy alone, or with hormones or chemotherapy).
  • One patient was unavailable for follow-up, another died of disseminated disease, and a third developed contralateral primary carcinoma.
  • CONCLUSIONS: The significant rate of axillary metastases in T1a and T1mic breast tumors makes axillary staging a must.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Lymph Node Excision. Lymphatic Metastasis / diagnosis

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413311.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C: Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol; 2004 Aug;14(8):1371-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy.
  • The accuracy of mammography, sonography and magnetic resonance imaging (MRI) in identifying residual disease after neoadjuvant chemotherapy is evaluated and imaging findings are correlated with pathologic findings.
  • Fifteen patients enrolled in an experimental protocol of preoperative neoadjuvant chemotherapy underwent clinical examination, mammography, sonography and dynamic MRI, performed in this order, before and respectively after 2 and 4 cycles of neoadjuvant chemotherapy.
  • MRI resulted in two false-negative results because of the presence of microfoci of in situ ductal carcinoma (DCIS) and invasive lobular carcinoma (LCI).
  • MRI assesses response to neoadjuvant chemotherapy better than traditional methods of physical examination and mammography.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging / methods. Neoadjuvant Therapy. Neoplasm, Residual / diagnosis. Ultrasonography, Mammary / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jan;17(1):110-9 [10458224.001]
  • [Cites] Radiology. 1995 Dec;197(3):743-7 [7480749.001]
  • [Cites] AJR Am J Roentgenol. 1999 Oct;173(4):911-7 [10511147.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Hong Kong Med J. 2000 Sep;6(3):265-8 [11025844.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):949-60 [1639655.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):537-40 [7884412.001]
  • [Cites] Br J Radiol. 1997 May;70(833):452-8 [9227225.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):416-23 [8004615.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):547-52 [7884414.001]
  • [Cites] Clin Radiol. 1993 May;47(5):339-44 [8508597.001]
  • [Cites] Radiology. 1993 May;187(2):493-501 [8475297.001]
  • [Cites] Radiology. 1999 Dec;213(3):881-8 [10580970.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):417-24 [9242745.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):91-100 [8646731.001]
  • [Cites] Radiology. 1996 Feb;198(2):333-40 [8596827.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):773-9 [9294574.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Radiology. 1996 Feb;198(2):327-32 [8596826.001]
  • [Cites] Radiology. 1994 Jun;191(3):633-8 [8184039.001]
  • [Cites] Radiology. 1989 Apr;171(1):95-103 [2648479.001]
  • [Cites] Eur Radiol. 2002 Jul;12(7):1711-9 [12111062.001]
  • [Cites] J Cancer Educ. 2002 Fall;17(3):138-41 [12243218.001]
  • [Cites] Radiology. 1989 Mar;170(3 Pt 1):681-6 [2916021.001]
  • [Cites] Radiol Med. 1998 May;95(5):449-55 [9687919.001]
  • (PMID = 14986052.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Kinkel K, Hylton NM: Challenges to interpretation of breast MRI. J Magn Reson Imaging; 2001 Jun;13(6):821-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges to interpretation of breast MRI.
  • This review describes the current knowledge and challenges of lesion interpretation with MRI of the breast according to different image interpretation strategies.
  • The impacts of the menstrual cycle, prior surgery, radiation therapy, and chemotherapy are summarized.
  • Particular enhancement features of ductal carcinoma in situ (DCIS) or invasive lobular carcinoma are described.
  • Finally, an adequate diagnosis at MRI of the breast should take into account the results of the patient's history, physical examination, and all imaging tests performed before MRI. J. Magn. Reson.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Lobular / diagnosis. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Image Enhancement

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11382939.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


11. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys; 2003 Jul 15;56(4):1038-45
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.
  • PURPOSE: To study the potential risk factors, including radiotherapy (RT) for contralateral breast cancer (CBC), in patients treated for early-stage breast cancer.
  • METHODS AND MATERIALS: The Surveillance, Epidemiology, and End Results database (1973-1996) was used to study the incidence of CBC after breast cancer.
  • Information on the use of hormonal therapy and chemotherapy was not available in the Surveillance, Epidemiology, and End Results database.
  • RESULTS: A CBC was documented in 5679 (4.2%) of the 134501 localized invasive or intraductal breast cancer patients surviving at least 3 months.
  • In multivariate analysis, medullary carcinoma (RR = 1.18, 95% confidence interval [CI] 1.02-1.37), black race (RR = 1.20, 95% CI 1.08-1.33), and age >55 years at initial diagnosis (RR = 1.15, 95% CI 1.08-1.22) were associated with increased CBC risk.
  • A total of 1234 (3.3%) of 37,379 patients who received RT developed CBC, and 4445 (4.6%) of 97122 patients who did not receive RT developed CBC.
  • The increased CBC risk with RT was evident in patients aged <45 years (RR = 1.32, p = 0.01) and >55 years (RR = 1.15, p = 0.04) at initial diagnosis.
  • CONCLUSION: CBC is not uncommon after breast cancer, especially for certain subsets of patients.
  • This minimal increase in CBC risk should not affect clinical decision-making in treatment selection for patients with localized invasive breast cancer or ductal carcinoma in situ.
  • Unnecessary radiation exposure to the contralateral breast should be avoided for all patients with early-stage breast cancer.
  • [MeSH-major] Breast Neoplasms / etiology. Breast Neoplasms / radiotherapy. Neoplasms, Second Primary / etiology. Radiation Injuries / etiology
  • [MeSH-minor] Age Factors. Carcinoma in Situ / epidemiology. Carcinoma in Situ / etiology. Carcinoma in Situ / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / epidemiology. Carcinoma, Intraductal, Noninfiltrating / etiology. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Female. Humans. Incidence. Middle Aged. Proportional Hazards Models. Radiotherapy / adverse effects. Risk Factors. SEER Program. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):920-1 [12829125.001]
  • (PMID = 12829139.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Hamada N, Ogawa Y, Nishioka A, Kariya S, Terashima M, Yoshida S, Tanaka Y, Inomata T: An elderly patient with DCIS of the breast effectively treated with toremifene alone. Oncol Rep; 2002 May-Jun;9(3):475-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An elderly patient with DCIS of the breast effectively treated with toremifene alone.
  • An elderly patient with breast cancer received toremifene monotherapy for one year, and about 60% tumor remission rate was obtained.
  • Since viability of the residual tumor was suspected on ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI), lumpectomy was performed under local anesthesia.
  • The histopathological diagnosis was ductal carcinoma in situ (DCIS).
  • The patient did not undergo axillary lymph node dissection or systemic chemotherapy.
  • The patient is alive without disease under postoperative radiotherapy and toremifene treatment.
  • Toremifene monotherapy and/or preoperative adjuvant therapy with toremifene alone may be useful methods for elderly patients with breast cancer considering the patients' quality of life.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Toremifene / therapeutic use
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Quality of Life. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11956612.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 7NFE54O27T / Toremifene
  •  go-up   go-down


13. Perera F, Yu E, Engel J, Holliday R, Scott L, Chisela F, Venkatesan V: Patterns of breast recurrence in a pilot study of brachytherapy confined to the lumpectomy site for early breast cancer with six years' minimum follow-up. Int J Radiat Oncol Biol Phys; 2003 Dec 1;57(5):1239-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of breast recurrence in a pilot study of brachytherapy confined to the lumpectomy site for early breast cancer with six years' minimum follow-up.
  • PURPOSE: In this pilot study of high-dose-rate brachytherapy to the lumpectomy site as the sole radiation, ipsilateral and contralateral breast recurrences are documented with specific attention to the location of recurrence relative to the lumpectomy site.
  • METHODS: Between March 1992 and January 1996, 39 patients with T1 (32 patients) and T2 breast cancers received 37.2 Gy in 10 fractions (b.i.d.) over 1 week prescribed to a volume encompassing the surgical clips.
  • Thirteen received adjuvant tamoxifen, and 4 received chemotherapy.
  • Follow-up included annual bilateral mammograms and clinical breast examination every 3 to 6 months.
  • The latter group and 7 of the former group had surgical clips marking the lumpectomy site, which allowed estimates of the distance of any ipsilateral breast recurrence from the lumpectomy site, using the mediolateral and cranio-caudad mammographic views.
  • The 5-year actuarial rate of ipsilateral breast recurrence was 16.2%.
  • One of the 2 patients had a 1-mm microscopic margin at initial diagnosis; the recurrence was a 3.5-mm microscopic focus of duct carcinoma in situ.
  • The other patient had a 1.5-cm, high-grade infiltrating mammary carcinoma with no residual at wider resection at first diagnosis; the 5-mm invasive recurrence was also of high grade.
  • Four women developed invasive recurrences at least 1.6 cm or more from the lumpectomy site (out-of-field recurrences).
  • Two of these women had gross multifocal recurrences with two cancers in each patient; 1 of the 2 patients had an extensive intraductal component at initial diagnosis.
  • All ipsilateral breast recurrences were salvaged by mastectomy (4 patients) or by repeat lumpectomy (2 patients) and whole-breast radiation.
  • There were two contralateral breast recurrences at intervals of 34 and 36 months; 1 of these patients also had a multifocal, ipsilateral recurrence at 58 months, as previously described.
  • Among patients with any breast recurrence, 1 patient had a family history of prostate cancer; there was no family history of breast or ovarian cancer.
  • Of 17 patients who received adjuvant systemic therapy, only 1 had a breast recurrence.
  • CONCLUSIONS: In this pilot study, breast recurrences outside of the lumpectomy site were the predominant pattern of recurrence.
  • [MeSH-major] Brachytherapy / methods. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Chemotherapy, Adjuvant. Dose Fractionation. Female. Follow-Up Studies. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Pilot Projects. Salvage Therapy. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1214-6 [14630253.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1210-3 [14630252.001]
  • (PMID = 14630257.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lauzier S, Maunsell E, Levesque P, Mondor M, Robert J, Robidoux A, Provencher L: Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer. Breast Cancer Res Treat; 2010 Apr;120(3):685-91
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychological distress and physical health in the year after diagnosis of DCIS or invasive breast cancer.
  • Ductal carcinoma in situ (DCIS) has an excellent prognosis, but its management can resemble that of early invasive breast cancer.
  • We compared aspects of quality of life of women with DCIS to that of women with invasive disease during the first year after treatment initiation.
  • Participants came from consecutive series of women with newly diagnosed, non-metastatic breast cancer treated in eight Quebec hospitals in 2003.
  • Data were obtained 1, 6, and 12 months after the start of treatment.
  • Women with DCIS reported significantly higher levels of physical health, particularly when compared at 1 month to women with invasive disease who had chemotherapy (P value < 0.0001; ES = 0.82).
  • Measured in symptoms of psychological distress, the better prognosis or less aggressive management of DCIS does not offset the general psychological effects of a cancer diagnosis to any great degree.
  • [MeSH-major] Breast Neoplasms / psychology. Carcinoma, Ductal, Breast / psychology. Carcinoma, Intraductal, Noninfiltrating / psychology. Health Status Indicators. Stress, Psychological / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / psychology. Female. Follow-Up Studies. Humans. Mastectomy / psychology. Middle Aged. Prognosis. Quality of Life. Radiotherapy, Adjuvant / psychology. Severity of Illness Index. Socioeconomic Factors. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653097.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


15. Zujewski JA, Kamin L: Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol; 2008 Oct;4(5):603-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trial assessing individualized options for treatment for breast cancer: the TAILORx trial.
  • Novel genetic profiling tests of breast cancer tissue have been shown to be prognostic for overall survival and predictive of local and distant rates of recurrence in breast cancer patients.
  • One of these tests, Oncotype DXtrade mark, is a diagnostic test comprised of a 21-gene assay applied to paraffin-embedded breast cancer tissue, which allows physicians to predict subgroups of hormone-receptor-positive, node-negative patients who may benefit from hormonal therapy alone or require adjuvant chemotherapy to attain the best survival outcome.
  • The results of the assay are converted to a recurrence score (0-100) that has been found to be predictive of 10- and 15-year local and distant recurrence in node-negative, estrogen-receptor-positive breast cancer patients.
  • Previous studies have shown that patients with high recurrence scores benefit from adjuvant chemotherapy, whereas patients with low recurrence scores do not.
  • To evaluate the ability to guide treatment decisions in the group with a mid-range recurrence score, the North American Cooperative Groups developed the Trial Assessing IndiviuaLized Options for Treatment for breast cancer, a randomized trial of chemotherapy followed by hormonal therapy versus hormonal therapy alone on invasive disease-free survival-ductal carcinoma in situ (IDFS-DCIS) survival in women with node-negative, estrogen-receptor-positive breast cancer with a recurrence score of 11-25.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Intraductal, Noninfiltrating. Chemotherapy, Adjuvant. Drug Resistance, Neoplasm / genetics. Female. Humans. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / genetics. Tamoxifen / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18922117.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


16. Sawai K, Nakajima H, Mizuta N, Sakaguchi K, Hachimine Y: [Key issues in sentinel node biopsy for breast cancer]. Gan To Kagaku Ryoho; 2004 Aug;31(8):1271-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Key issues in sentinel node biopsy for breast cancer].
  • Whereas the majority of surgeons in Western countries perform sentinel node biopsy (SNB) for early breast cancer, the majority of Japanese surgeons do not.
  • Veronesi very recently reported the results of a clinical trial in which SNB without axillary lymph node dissection for small breast cancer did not increase axillary recurrence.
  • Thus, sentinel node surgery has been accepted as a safe and accurate method of screening the axillary nodes for metastasis in women with small breast cancer.
  • SNB should thus be recommended as standard care for early breast cancer in Japan.
  • SNB for patients with ductal carcinoma in situ (DCIS) may be performed according to the decision of doctors or patients in each case, because the indication of SNB for DCIS is controversial.
  • Since preoperative chemotherapy could increase the rate of false-negative sentinel nodes because of the induced lymphatic changes, SNB is thought to be safer before than after preoperative chemotherapy.
  • Current evidence does not allow internal mammary SNB to be recommended as a standard procedure, but as patients with internal mammary node involvement may benefit from adjuvant systemic treatment, internal mammary SNB should be further studied in this context.
  • Preoperative diagnosis of an axillary metastasis using fine-needle aspiration cytology (FNAC) under ultrasonographical imaging or core needle biopsy under MR imaging can cost-effectively decrease the indications of SNB.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Staging / classification. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Sternum

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15332557.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


17. Page DL, Simpson JF: Pathology of preinvasive and excellent-prognosis breast cancer. Curr Opin Oncol; 2000 Nov;12(6):526-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of preinvasive and excellent-prognosis breast cancer.
  • Our review of recent developments in breast cancer emphasizes clinical utility of tissue samples from patients.
  • We highlight indicators of increased cancer risk and lesions without metastatic capacity at time of detection (but of sufficient risk of attaining metastatic capacity that treatment is mandated, ie, ductal carcinoma in situ).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11085451.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 33
  •  go-up   go-down


19. Jhingran A, Kim JS, Buchholz TA, Katz A, Strom EA, Hunt KK, Sneige N, McNeese MD: Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: The University of Texas M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys; 2002 Nov 1;54(3):804-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: The University of Texas M. D. Anderson Cancer Center experience.
  • PURPOSE: To analyze the long-term outcome of breast conservation therapy in patients with ductal carcinoma in situ (DCIS) in a single institution and to analyze the prognostic importance, if any, of young patient age.
  • Local recurrence correlated with nuclear grade (p = 0.002) but was not associated with patient age at diagnosis (<40 years vs. >or=40 years, p = 0.39).
  • In all cases of local recurrence, patients underwent surgery with or without chemotherapy, and disease control was achieved.
  • CONCLUSION: The results of this study demonstrate high rates of long-term overall survival, disease-specific survival, and local control in patients with DCIS of the breast treated conservatively with segmental mastectomy and radiotherapy.
  • Continued studies in young patients treated with breast conservative therapy for DCIS are needed.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Middle Aged. Recurrence. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12377332.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


20. Sharp K: Atypical fatigue. Clin J Oncol Nurs; 2007 Oct;11(5):628-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE STUDY: Mrs. S is a 63-year-old retired teacher who returns to the office for breast cancer follow-up.
  • She was diagnosed with intraductal carcinoma, and her treatment included a modified radial mastectomy followed by four cycles of doxorubicin and cyclophosphamide.
  • Her tumor was estrogen receptor-positive, progesterone receptor-positive, and human epidermal growth factor receptor 2-negative by fluorescence in-situ hybridization.
  • Chemotherapy was completed nine months ago, and she is taking adjuvant tamoxifen.
  • She states, "I expected to be tired during and immediately after chemotherapy, but I thought I would have all my energy back by now.
  • In fact, I feel sleepy all the time!
  • She has not exercised since her breast cancer diagnosis but has been trying to lose weight with dietary changes.
  • She takes no other medications.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma, Intraductal, Noninfiltrating / complications. Fatigue / diagnosis. Fatigue / etiology. Sleep Apnea, Obstructive
  • [MeSH-minor] Causality. Comorbidity. Continuous Positive Airway Pressure. Diagnosis, Differential. Female. Humans. Hypertension / complications. Medical History Taking. Middle Aged. Nurse Practitioners. Nurse's Role. Nursing Assessment. Obesity / complications. Oncology Nursing. Polysomnography. Risk Assessment






Advertisement